New and old technologies for organ replacement

aDepartment of Surgery bDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Current opinion in organ transplantation (Impact Factor: 2.88). 02/2013; 18(2). DOI: 10.1097/MOT.0b013e32835f0887
Source: PubMed


Purpose of review:
The demand for organ transplantation has increased over time, increasingly exceeding the supply of organs. Whether and how new or old technologies separately or together could be applied to replacing organs will thus remain a question of importance.

Recent findings:
Estimating how the demand for organ transplantation will evolve over the decades and the need to bring forward and test new technologies will help establish the dimensions of the problem and the priorities for investigation. Pluripotent stem cells can in principle expand to sufficient numbers, differentiate, and assemble complex and functional organs. However, the devising of effective and reliable means to coax the stem cells to do so remains beyond the current grasp.

Given the time during which novel therapies are devised and applied, which organ transplantation reaches to 2-3 decades, one can anticipate the need for organ replacement will grow dramatically, but advances in science and technology will overcome the hurdles in generating new organs. Whether these advances will address the needs and priorities of society, however, is unclear.

22 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: One in ten Americans suffer from chronic kidney disease, and close to 90,000 people die each year from causes related to kidney failure. Patients with end-stage renal disease are faced with two options: hemodialysis or transplantation. Unfortunately, the reach of transplantation is limited because of the shortage of donor organs and the need for immunosuppression. Bioengineered kidney grafts theoretically present a novel solution to both problems. Herein we discuss the history of bioengineering organs, the current status of bioengineered kidneys, considerations for the future of the field, and challenges to clinical translation. We hope that by integrating principles of tissue engineering, and stem cell and developmental biology, bioengineered kidney grafts will advance the field of regenerative medicine while meeting a critical clinical need.
    Seminars in Nephrology 07/2014; 34(4). DOI:10.1016/j.semnephrol.2014.06.005 · 3.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A variety of diseases may lead to hysterectomies or uterine injuries, which may form a scar and lead to infertility. Due to the limitation of native materials, there are few effective methods to treat such damages. Tissue engineering combines cell and molecular biology with materials and mechanical engineering to replace or repair damaged organs and tissues. The use of human embryonic stem cells (hESCs) as a donor cell source for the replacement therapy will require the development of simple and reliable cell differentiation protocols. This study aimed to efficiently generate endometrium-like cells from the hESCs and use these cells with collagen scaffold to repair uterine damage. The hESCs were induced by co-culturing with endometrial stromal cells, and at the same time added cytokines: epidermal growth factor (EGF), platelet derived growth factor-b (PDGF-b) and E2. Expression of cell specific markers was analyzed by immunofluorescence and RT-PCR to monitor the progression toward an endometrium-like cell fate. After differentiation, the majority of cells (> 80%) were positive for cytokeratin-7, and the expression of key transcription factors related to endometrial development, such as Wnt4, Wnt7a, Wnt5a, Hoxa11, and factors associated with endometrial epithelial cells function: Hoxa10, Intergrinβ3, LIF, ER and PR were also detected. Then we established the uterine full-thickness-injury rat models to test cell function in vivo. Human embryonic stem cell-derived cells (hESC-derived cells) were dropped onto collagen scaffolds and transplanted into the animal model. 12 weeks after transplantation, we discovered that the hESC-derived cells could survive and recover the structure and function of uterine horns in a rat model of severe uterine damage. The experimental system presented here provides a reliable protocol to produce endometrium-like cells from hESCs. And our results encourage the use of hESCs in cell-replacement therapy for severe uterine damage in future.
    Tissue Engineering Part A 08/2014; 21(1-2). DOI:10.1089/ten.TEA.2014.0052 · 4.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Organ transplantation represents a unique method of treatment to cure people with end-stage organ failure. Since the first successful organ transplant in 1954, the field of transplantation has made great strides forward. However, despite the ability to transform and save lives, transplant surgery is still faced with a fundamental problem the number of people requiring organ transplants is simply higher than the number of organs available. To put this in stark perspective, because of this critical organ shortage 18 people every day in the United States alone die on a transplant waiting list (U.S. Department of Health & Human Services, To address this problem, attempts have been made to increase the organ supply through xenotransplantation and more recently, bioengineering. Here we trace the development of both fields, discuss their current status and highlight limitations going forward. Ultimately, lessons learned in each field may prove widely applicable and lead to the successful development of xenografts, bioengineered constructs, and bioengineered xeno-organs, thereby increasing the supply of organs for transplantation. Copyright © 2014. Published by Elsevier Ltd.
    International Journal of Surgery (London, England) 12/2014; 13. DOI:10.1016/j.ijsu.2014.12.011 · 1.53 Impact Factor
Show more